FSD Pharma Inc.
HUGE · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.83 | 13.04 | -7.06 | 7.90 |
| FCF Yield | -0.11% | -0.07% | -0.04% | -0.06% |
| EV / EBITDA | -177.08 | -1,290.96 | -1,537.87 | -973.37 |
| Quality | ||||
| ROIC | -31.92% | -18.59% | -15.66% | -21.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.18 | 0.94 | 0.52 | 1.51 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 69.13% | -121.18% | 48.14% | 51.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.84 | 0.33 | 1.57 | 1.03 |
| Interest Coverage | -413.62 | -181.84 | -172,083.83 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 62,797.00 | 0.42 |
| Cash Conversion Cycle | 0.00 | -1,975.26 | -2,322.24 | -1,439.08 |